KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Current Deferred Revenue (2016)

Gilead Sciences (GILD) has disclosed Current Deferred Revenue for 8 consecutive years, with $202.0 million as the latest value for Q4 2016.

  • For the quarter ending Q4 2016, Current Deferred Revenue fell 54.09% year-over-year to $202.0 million, compared with a TTM value of $202.0 million through Dec 2016, down 54.09%, and an annual FY2016 reading of $202.0 million, down 54.09% over the prior year.
  • Current Deferred Revenue was $202.0 million for Q4 2016 at Gilead Sciences, down from $361.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $529.0 million in Q1 2016 and bottomed at $93.7 million in Q2 2012.
  • Average Current Deferred Revenue over 5 years is $214.2 million, with a median of $126.8 million recorded in 2013.
  • The sharpest move saw Current Deferred Revenue soared 296.72% in 2015, then plummeted 54.09% in 2016.
  • Year by year, Current Deferred Revenue stood at $103.2 million in 2012, then rose by 7.6% to $111.0 million in 2013, then grew by 20.72% to $134.0 million in 2014, then skyrocketed by 228.36% to $440.0 million in 2015, then tumbled by 54.09% to $202.0 million in 2016.
  • Business Quant data shows Current Deferred Revenue for GILD at $202.0 million in Q4 2016, $361.0 million in Q3 2016, and $345.0 million in Q2 2016.